CD24 and neoplasm: First, we found that the expression of CD24 was higher in the tumor tissues than adjacent tissues; moreover, the clinically diagnosed sorafenib-resistant tumor tissues (n = 13) expressed higher levels of CD24 compared to the non-sorafenib-resistant tissues (n = 57) (Fig. 1a).